Skip to main content
Clinical Trials/NCT06666816
NCT06666816
Recruiting
Not Applicable

Observational Study for the Identification of Fatigue and Gait Biomarkers in Populations With Neuromuscular Pathologies in the Clinical Context and Daily Life

IRCCS Eugenio Medea2 sites in 1 country120 target enrollmentOctober 27, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Muscular Dystrophies
Sponsor
IRCCS Eugenio Medea
Enrollment
120
Locations
2
Primary Endpoint
Variation in walking speed during a 6-minutes walking test
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore, the investigators want to evaluate the feasibility of collecting physical activity in daily life conditions during a one-week monitoring period using a wearable sensor.

Registry
clinicaltrials.gov
Start Date
October 27, 2017
End Date
December 1, 2026
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
IRCCS Eugenio Medea
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ambulant adult patients with genetic diagnosis of muscular dystrophy/myopathy (dystrophinopathies, muscular dystrophies and congenital and non-congenital myopathies), of spinal muscular atrophy (SMA) and with molecular diagnosis of Charcot-Marie Tooth 1 or
  • independent walking, even with assistance;

Exclusion Criteria

  • Dilated or ischemic heart disease with moderate impairment;
  • Chronic respiratory failure: forced vital capacity (FVC) \< 40%; more than 5% of nocturnal time spent with peripheral oxygen saturation levels \< 90.

Outcomes

Primary Outcomes

Variation in walking speed during a 6-minutes walking test

Time Frame: Baseline

Variation in walking speed calculated as difference between the first and the final minute of the a 6-minutes walking test

Subjective fatigue

Time Frame: Baseline

Evaluation of subjective fatigue using the Fatigue Severity Scale (FSS). The minimum value is 0, the maximum is 63. Higher scores mean worse outcome.

Secondary Outcomes

  • Clinical progression of the neuromuscular disease(Baseline)
  • Variation in gait variability during the 6-Minutes Walking Test(Baseline)

Study Sites (2)

Loading locations...

Similar Trials